alexa Immune Responses To HPV Vaccines: What We Have Learned
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference and Exhibition on Clinical & Cellular Immunology
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Ligia A Pinto
ScientificTracks Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899.S1.017
Abstract
There are two licensed prophylactic human papillomavirus (HPV) vaccines, aquadrivalent that protects primarily against HPV-16, HPV -18, HPV-6 and HPV-11and a bivalent vaccine that protects primarily against HPV-16 and HPV-18. These L1 VLP vaccines have proven to be very efficacious in preventing infections and pre-cancerous lesions at the cervix caused by HPV-16 and HPV-18. Furthermore, partial protection against phylogenetically-related oncogenic types not included in the vaccine has also been reported. Although correlates of vaccine protection have not been identified, neutralizing antibodies are thought to be the primary mechanism of vaccine induced protection against infection. HPV vaccines induce high titers of anti-L1 IgG antibodies, to the HPV types included in the vaccine, that persist for several years after vaccination at levels considerably higher than those observed in natural infection. These antibodies are detected not only inserum but also at the cervix, where local antibody levels correlate well with serum levels. L1 VLP vaccines also induce neutralizing antibodies to phylogenetically-related types not included in the vaccine. These can also persist for years after vaccination but withtiters much lower than those observed for the homologous vaccine types. Antibody avidity increases with each dose of vaccine, with affinity maturation occurring after the 3 doses of vaccine. Interestingly, levels of avidity did not appear to correlate well with antibody titers. Despite all the information on antibody responses to HPV vaccines, future efforts are needed to standardizemethods and tools for evaluation of immunogenicity of HPV vaccines and to better identify mechanisms of immunogenicity and correlates of protection against infection.
Biography
Ligia A Pinto completed her PhD in 1995 at the Experimental Immunology Branch, National Institutes of Health, after several years of research on cellular immunology of HIV infection at the University of Lisbon, School of Medicine in Portugal. She continued her Postdoctoral studies at NIH where she focused on investigating immunological alterations induced by HIV as well as host protective immune responses that may control HIV replication and associated immunopathogenesis. In 2001, she became the head of the HPV Immunology Laboratory at the Frederick National Laboratory, where she is a Principal Investigator and leads a team of Scientists, Postdoctoral Fellows, Research Associates and Students. She has worked in the area of immunology of infectious diseases and vaccines for the last 27 years, with over 80 peer-reviewed publications, has many invited international presentations and received a number of distinguished scientific awards.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version